Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPY4R | P50391 | 9/20 | 0.35 |
| ▸ | NPY1R | P25929 | 7/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.35 |
| ▸ | NPY2R | P49146 | 3/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.34 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16263588 | 0.86 | DNM1 (0.36) | HPGDNPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL16260299 | 0.85 | SIRT6 (0.40) | NPY4RNPY1RNPY5RNPY2RSIRT6 | |
| SCHEMBL16260140 | 0.85 | SIRT6 (0.40) | NPY4RNPY1RNPY5RNPY2RSIRT6 | |
| SCHEMBL16260290 | 0.85 | SIRT6 (0.43) | NPY4RNPY1RNPY5RNPY2RSIRT6 | |
| SCHEMBL16260144 | 0.85 | SIRT6 (0.43) | NPY4RNPY1RNPY5RNPY2RSIRT6 | |
| SCHEMBL27113032 | 0.84 | SIRT6 (0.48) | SIRT6SIRT1 | |
| SCHEMBL27114204 | 0.83 | SIRT6 (0.50) | SIRT6SIRT1 | |
| SCHEMBL12837508 | 0.82 | NPY4R (0.39) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL16263607 | 0.82 | SIRT6 (0.38) | NPY4RNPY1RNPY5RNPY2RSIRT6 | |
| SCHEMBL20620313 | 0.81 | NPY4R (0.32) | NPY4RNPY1RNPY5RNPY2RKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190002429-A1 | Derivatives of Xanthone Compounds | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2019-01-03 | — | — | US | disclosed |
| US-20140349918-A1 | DERIVATIVES OF XANTHONE COMPOUNDS | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2014-11-27 | — | — | US | disclosed |
| US-20140349918-A1 | DERIVATIVES OF XANTHONE COMPOUNDS | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002429-A1 | Derivatives of Xanthone Compounds | XDH, XPA, SQLE | HPGD 208/4885NPY4R 1057/4885NPY1R 927/4885 |
| US-20140349918-A1 | DERIVATIVES OF XANTHONE COMPOUNDS | XDH, XPA, SQLE | HPGD 208/4885NPY4R 1057/4885NPY1R 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.